Australia and New Zealand Opioid Use Disorder Treatment Market

Australia and New Zealand Opioid Use Disorder Treatment Market Size and Outlook (2025 to 2035)

Australia and New Zealand have been experiencing the Opioid Use Disorder (OUD) treatment market gradually increase at a steady pace. The addiction rate is rising in these countries. There is a growing access to various treatments available and heightened awareness. The market is expected to reach USD 16.0 million by 2025 and is likely to grow at an estimated 4.6% CAGR from 2025 to 2035.

Prescription misuse and illicit opioid use remain significant challenges for both countries. The governments are actively addressing all these issues with medication-assisted treatment, behavioral therapies, and harm reduction policies that are intertwined with healthcare reform initiatives. All these efforts work to ensure that necessary treatments reach the right hands.

Advances in digital health, telemedicine, and long-acting drug formulations are enhancing care by improving accessibility and delivery. Additionally, increased public awareness campaigns are helping to reduce the stigma associated with treatment, which is likely to further support market growth.

Attributes	Details
Estimated Value (2025)	USD 16.0 million
Value-based CAGR (2025 to 2035)	4.6%

Key Trends Shaping the Dual-Market Response to Opioid Use Disorder in Australia and New Zealand

• Escalating Medication-Assisted Treatment (MAT) Adoption: MAT is the established treatment in Australia and New Zealand for OUD, methadone and buprenorphine leading in use because of their evidence to reduce both craving and withdrawal.
• Increase of Harm-Reduction Programs: Drug use is eased and overdoses reduced with the addition of various forms of harm reduction-initiated interventions, such as needle exchange and supervised injecting facilities, along with treatments for OUD.
• Digital Health and Telemedicine: Telehealth platforms are increasingly important in facilitating OUD care, especially for rural and underserved populations. These platforms provide for online counseling, MAT management, and follow-up care.
• Focus on Indigenous and Marginalized Communities: Efforts are increasing to address the disproportionate impact of opioid addiction on Indigenous populations and other marginalized groups. Tailored programs provide culturally sensitive treatment and support.
• Growth in Extended-Release Therapies: Efforts are increasing to address the disproportionate impact of opioid addiction on Indigenous populations and other marginalized groups. Tailored programs provide

Industry-Wise Growth Patterns in Public Health, Private Clinics, and Correctional Rehabilitation

Industry	Growth Trends
Primary Healthcare	General practitioners play a key role in prescribing MAT, ensuring accessibility in urban and rural areas.
Specialized Clinics	OUD treatment centers offer comprehensive care, including MAT and behavioral therapies.
Telemedicine	Remote care platforms grow as vital tools for managing OUD, especially in remote areas of Australia and New Zealand.

Market Segmentation by Treatment Type Including MAT, Counseling, Digital Therapy, and Inpatient Detox

• Opioid Antagonists: Opioid antagonists are substances that block the activation of opioid receptors by opioids. They are commonly used to reverse opioid overdoses and play a role in relapse prevention therapy in Germany, with naloxone and naltrexone being key examples.
• Opioid Agonists and Partial Agonists: Partial agonists bind to opioid receptors but do not fully activate them, as is the case with full agonists, thereby lowering the risk of respiratory depression and addiction. The most commonly used partial agonist in Germany is buprenorphine, which has become the foundation for most medication-assisted treatment (MAT) programs used in the treatment of opioid use disorder.

Humanized Perspective on Growth Including Access Disparities, Rural Reach, and Social Programs

Opioid use disorder is not just a statistic; it represents a profound personal crisis affecting individuals, families, and communities throughout Australia and New Zealand. General practitioners, counselors, and harm-reduction advocates are at the forefront, offering essential compassionate care to support patients on their recovery journeys.

Market Concentration Across Public Providers, NGO-Led Clinics, and Private Telehealth Platforms

The OUD treatment market in Australia and New Zealand is moderately consolidated, with global pharmaceutical companies leading MAT solutions and local innovators contributing to harm-reduction and digital health initiatives.

Analyst Perspective

Global players like Indivior and Alkermes dominate the MAT segment with high-performance drugs such as Suboxone and Vivitrol. Domestic organizations, including Aboriginal Medical Services and Harm Reduction Australia, play crucial roles in delivering culturally appropriate care and supporting underserved populations. Collaborative efforts between international and local players strengthen the market’s reach and impact.

Vendor Tier	Tier 1
Key Vendors	Indivior, Alkermes, Camurus
Market Share (%)	60%
Description	Global leaders offering MAT solutions, including long-acting buprenorphine and extended-release naltrexone.

Vendor Tier	Tier 2
Key Vendors	Teva Pharmaceuticals, Aspen Pharma
Market Share (%)	25%
Description	Regional manufacturers providing affordable MAT options and generic formulations.

Vendor Tier	Tier 3
Key Vendors	Harm Reduction Australia, Telehealth NZ
Market Share (%)	15%
Description	Non-profits and digital health platforms delivering accessible and innovative care solutions.

Drivers of Growth Including Policy Expansion, Government Subsidies, and Digital Access

• High Prevalence of Opioid Addiction: Opioid Addiction Highly Prevalent in Australia and New Zealand. The misuse of prescription opioids and heroin addiction continues to rise in Australia and New Zealand, thus increasing the demand for effective treatments.
• Strong Government Support: Governments in both countries provide funding for MAT programs, harm-reduction initiatives, and research into innovative OUD treatments.
• Advancements in MAT Formulations: Extended-release medications, such as weekly and monthly injectable buprenorphine, improve adherence and reduce the risk of misuse.
• Focus on Rural and Remote Areas: Telemedicine service and outreach programmes help patients reach the treatment who live in rural and far-flung locations by overcoming geographic barriers.
• Public Health Campaigns to Reduce Stigma: Raising awareness through programs helps them overcome the hurdle of stigma, misinformation, or misconceptions for treatment.

Challenges and Restraints Around Stigma, Provider Shortages, and Prescription Regulation

• Stigma and Societal Perceptions: Many individuals delay seeking treatment due to fear of judgment, perpetuating the cycle of addiction.
• High Costs of Advanced Therapies: Extended-release formulations and digital health solutions, while effective, can be expensive, limiting their adoption in underserved areas.
• Barriers to Indigenous Access: Indigenous communities face unique challenges, including cultural sensitivities and limited access to specialized care, requiring targeted interventions.

Recent Industry Updates Covering Pilot Programs, Insurance Shifts, and Technology Integrations

Date	Company
Jan 2024	Indivior
Jul 2024	Alkermes
Nov 2024	Camurus

Date	Update
Jan 2024	Released an extended-release injectable buprenorphine for weekly and monthly dosing in Australia.
Jul 2024	Partnered with rehabilitation centers in New Zealand to distribute extended-release naltrexone.
Nov 2024	Expanded distribution of Buvidal (buprenorphine) to rural clinics across Australia and New Zealand.

Future Outlook for the OUD Treatment Market in ANZ with Emphasis on Multi-Channel Care Models and Early Intervention Systems

The opioid use disorder treatment market in Australia and New Zealand would exceed USD 32.5 million by 2035, all due to novel therapies, increased public health activity, and ever-growing digital solutions for health purposes.

As governments continue to place a premium on OUD management, use of MAT and other harm-reduction approaches will grow. Advances in telemedicine and digital therapeutics will further make the treatment available for rural and Indigenous populations. Public education will be paramount in reducing stigma and encouraging earlier interventions.

Top Segments Studied in Australia and New Zealand Market: Therapy Type, Patient Profile, Care Delivery Mode, and Region

By Drug Class:

In terms of drug class, the industry is divided into opioid antagonists (naloxone, naltrexone), opioid agonists and partial agonists (methadone, buprenorphine)

By Indication:

In terms of indication, the industry is segregated into pain management, opioid withdrawal/opioid use disorder (Opioid Use Disorder), alcohol de-addiction, depression.

By End User:

In terms of end user, the industry is divided into hospitals, rehabilitation centers, community health clinics and home-based care.